442 related articles for article (PubMed ID: 29682504)
41. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
42. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
43. Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.
Calzetta L; Ritondo BL; Matera MG; Facciolo F; Rogliani P
Br J Pharmacol; 2020 Oct; 177(20):4750-4765. PubMed ID: 32857420
[TBL] [Abstract][Full Text] [Related]
44. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review.
Patterson MF; Borish L; Kennedy JL
J Asthma Allergy; 2015; 8():125-34. PubMed ID: 26604804
[TBL] [Abstract][Full Text] [Related]
45. Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief.
Massey OW; Suphioglu C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232470
[TBL] [Abstract][Full Text] [Related]
46. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.
Janson C; Bjermer L; Lehtimäki L; Kankaanranta H; Karjalainen J; Altraja A; Yasinska V; Aarli B; Rådinger M; Hellgren J; Lofdahl M; Howarth PH; Porsbjerg C
Eur Clin Respir J; 2022; 9(1):2040707. PubMed ID: 35251534
[TBL] [Abstract][Full Text] [Related]
47. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.
Menzella F; Lusuardi M; Galeone C; Taddei S; Zucchi L
J Asthma Allergy; 2015; 8():105-14. PubMed ID: 26504401
[TBL] [Abstract][Full Text] [Related]
48. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
49. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
50. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
51. Reductions in eosinophil biomarkers by benralizumab in patients with asthma.
Pham TH; Damera G; Newbold P; Ranade K
Respir Med; 2016 Feb; 111():21-9. PubMed ID: 26775606
[TBL] [Abstract][Full Text] [Related]
52. Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma.
Kim JH; Kim DS; Park HS; Kim YS
Clin Immunol; 2023 Oct; 255():109755. PubMed ID: 37673224
[TBL] [Abstract][Full Text] [Related]
53. Biologic therapies targeting eosinophils: current status and future prospects.
Legrand F; Klion AD
J Allergy Clin Immunol Pract; 2015; 3(2):167-74. PubMed ID: 25754717
[TBL] [Abstract][Full Text] [Related]
54. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
[TBL] [Abstract][Full Text] [Related]
55. Anti-IL-5 in pediatric allergic diseases.
Tenero L; Arturi E; Piazza M; Piacentini G
Pediatr Allergy Immunol; 2020 Nov; 31 Suppl 26():14-16. PubMed ID: 33236428
[TBL] [Abstract][Full Text] [Related]
56. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
[TBL] [Abstract][Full Text] [Related]
57. Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
Varricchi G; Senna G; Loffredo S; Bagnasco D; Ferrando M; Canonica GW
Front Immunol; 2017; 8():242. PubMed ID: 28344579
[TBL] [Abstract][Full Text] [Related]
58. Benralizumab as a potential treatment of asthma.
Antoniu SA
Expert Opin Biol Ther; 2017 Jul; 17(7):895-900. PubMed ID: 28406319
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-13 in Asthma and Other Eosinophilic Disorders.
Doran E; Cai F; Holweg CTJ; Wong K; Brumm J; Arron JR
Front Med (Lausanne); 2017; 4():139. PubMed ID: 29034234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
